Virtus LifeSci Biotech Products ETF (BBP) Performance
BBP total return
Distributions reinvested · as of Oct 23, 2026- YTD
- +27.7% since Dec 31, 2025
- 1 year
- +41.5% total return
- 5 years
- +15.0% a year
- 10 years
- +12.9% a year
- Since first price
- +12.4% a year since 2014
BBP trailing returns vs SPY, QQQ, AGG
| Period | BBP total return | Price only | S&P 500 (SPY) | Nasdaq-100 (QQQ) | U.S. bonds (AGG) |
|---|---|---|---|---|---|
| 1 month | −2.4% | −2.4% | −1.0% | −5.0% | +0.9% |
| 3 months | +4.9% | +4.9% | +3.2% | +1.9% | −0.4% |
| 6 months | +18.6% | +18.6% | +7.8% | +8.4% | −1.5% |
| YTD | +27.7% | +27.7% | +12.3% | +15.1% | −1.0% |
| 1 year | +41.5% | +41.5% | +14.4% | +15.9% | −1.1% |
| 3 years | +120.8%+30.2%/yr | +120.8% | +87.4%+23.3%/yr | +101.4%+26.3%/yr | +16.6%+5.2%/yr |
| 5 years | +101.0%+15.0%/yr | +101.0% | +79.3%+12.4%/yr | +94.0%+14.2%/yr | −0.8%−0.2%/yr |
| 10 years | +236.8%+12.9%/yr | +236.2% | +315.9%+15.3%/yr | +538.9%+20.4%/yr | +14.0%+1.3%/yr |
| Since inceptionDec 17, 2014 | +297.7%+12.4%/yr | +291.8% | — | — | — |
Total return from adjusted closes (distributions reinvested, before tax). Periods of 3 years or more are also shown annualized. Price only excludes distributions.
Growth of $10,000: BBP vs SPY
From Dec 17, 2014: BBP grew to $39,774, SPY to $45,960.
Year-end values with distributions reinvested, no taxes or trading costs. Start: first common trading day of both funds.
BBP returns by calendar year
9 of 11 full years positive. Best 2025 (+33.2%), worst 2018 (−14.0%). 2026 is year to date.
BBP annual returns table
| Year | BBP | Largest drop | SPY | QQQ | AGG |
|---|---|---|---|---|---|
| 2026YTD | +27.7% | −9.4% | +12.3% | +15.1% | −1.0% |
| 2025 | +33.2% | −21.1% | +17.7% | +20.8% | +7.2% |
| 2024 | +3.3% | −19.8% | +24.9% | +25.6% | +1.3% |
| 2023 | +17.9% | −17.9% | +26.2% | +54.9% | +5.7% |
| 2022 | +0.9% | −31.4% | −18.2% | −32.6% | −13.0% |
| 2021 | −8.2% | −26.2% | +28.7% | +27.4% | −1.8% |
| 2020 | +22.2% | −30.5% | +18.3% | +48.6% | +7.5% |
| 2019 | +24.7% | −24.9% | +31.2% | +39.0% | +8.5% |
| 2018 | −14.0% | −31.5% | −4.6% | −0.1% | +0.1% |
| 2017 | +24.1% | −10.4% | +21.7% | +32.7% | +3.6% |
| 2016 | +6.3% | −25.9% | +12.0% | +7.1% | +2.4% |
| 2015 | +19.6% | −29.0% | +1.2% | +9.4% | +0.5% |
Largest drop = deepest fall from a high within that calendar year.
Calendar-year return vs largest drop within the year
Most years include a sizable fall at some point even when the year ends higher.
BBP largest drawdowns
Now 7.1% below the high| Peak | Decline | Bottom | Recovered | Fall | Underwater |
|---|---|---|---|---|---|
| Feb 8, 2021 | −44.3% | May 9, 2022 | Feb 27, 2024 | 1.2 years | 3.0 years |
| Jul 20, 2015 | −40.5% | Feb 11, 2016 | Feb 9, 2017 | 7 months | 1.6 years |
| Jul 13, 2018 | −32.2% | Mar 16, 2020 | May 11, 2020 | 1.7 years | 1.8 years |
| Nov 8, 2024 | −26.1% | Apr 10, 2025 | Sep 2, 2025 | 5 months | 10 months |
| Feb 27, 2024 | −19.8% | Apr 18, 2024 | Jul 15, 2024 | 51 days | 5 months |
| Jan 29, 2018 | −12.4% | Feb 9, 2018 | Jun 19, 2018 | 11 days | 5 months |
Declines from a closing high (distributions reinvested) of 10% or more. Underwater = time from the peak until the old high was regained.
BBP risk statistics
| Statistic | 3 years | 5 years | 10 years | Since 2014 |
|---|---|---|---|---|
| Annualized return | +28.3% | +15.7% | +12.2% | +12.8% |
| Volatility (annualized) | 19.3% | 19.9% | 22.5% | 24.0% |
| Sharpe ratio | 1.17 | 0.66 | 0.53 | 0.54 |
| Sortino ratio | 2.29 | 1.09 | 0.85 | 0.84 |
| Best month | +13.8% | +13.8% | +17.9% | +17.9% |
| Worst month | −8.6% | −11.8% | −20.0% | −22.2% |
| Best 12 months | +65.3% | +65.3% | +65.3% | +65.3% |
| Worst 12 months | −1.8% | −10.9% | −28.1% | −28.1% |
| Positive months | 64% | 60% | 58% | 59% |
| Beta vs S&P 500 | 0.68 | 0.57 | 0.77 | — |
| Correlation with S&P 500 | 0.44 | 0.45 | 0.52 | — |
From monthly total returns. Sharpe and Sortino use 1–3 month T-bills (BIL) as the risk-free rate, so they need history from 2007 on.
BBP rolling returns
| Holding period | Periods | Worst | Median | Best | Positive |
|---|---|---|---|---|---|
| 1-year | 131 | −28.1% | +11.3% | +65.3% | 73% |
| 3-year (a year) | 107 | −2.6% | +8.0% | +29.8% | 93% |
| 5-year (a year) | 83 | +0.3% | +7.7% | +19.1% | 100% |
| 10-year (a year) | 23 | +5.4% | +9.9% | +14.0% | 100% |
Every holding period starting at a month-end since 2014. Returns for 3 years and longer are annualized.
BBP performance overview
Virtus LifeSci Biotech Products ETF (BBP) returned +41.5% over the past year and +12.9% a year over ten years, with distributions reinvested. Since its first recorded price in 2014 it has returned +12.4% a year, turning $10,000 into about $39,774. Over the same year S&P 500 (SPY) returned +14.4%.
The deepest decline was −44.3%, from Feb 8, 2021 to May 9, 2022, and it took 1.8 years to get back to the old high. BBP finished 9 of its 11 full calendar years with a gain; the best year was 2025 (+33.2%) and the worst 2018 (−14.0%). Volatility has been 24.0% a year.
Related: BBP chart, BBP holdings. See the BBP overview for the latest quote and fund facts.
BBP performance FAQ
What is the BBP return over the past year?
BBP returned +41.5% over the 12 months to October 23, 2026, including reinvested distributions. On price alone it rose 41.5%.
What is the average annual return of BBP?
BBP has returned +15.0% a year over 5 years, +12.9% a year over 10 years, +12.4% a year since December 17, 2014 (total return, distributions reinvested).
How much would $10,000 invested in BBP be worth?
$10,000 invested in BBP at its first recorded close on December 17, 2014 would be worth about $39,774 on October 23, 2026 with distributions reinvested.
What was the worst year for BBP?
The worst calendar year was 2018, with a total return of −14.0%. The best was 2025 at +33.2%.
What is the biggest drawdown of BBP?
The largest peak-to-trough decline was −44.3% between February 8, 2021 and May 9, 2022. It recovered to the old high on February 27, 2024, 1.8 years after the bottom.
How volatile is BBP?
Over the past 3 years BBP had an annualized volatility of 19.3% and a Sharpe ratio of 1.17 (excess return over 1–3 month T-bills per unit of risk).